In recent months, the United Kingdom Health Security Agency (UKHSA) has issued a groundbreaking warning to the public about a potentially deadly virus – hepatitis C (HCV). estimate that around 50 million individuals globally live with chronic hepatitis C (CHV), with about 1 million new cases being reported each year. This warning has ignited widespread concern within the UK and beyond, as HCV remains a leading cause of preventable death, with an estimated 242,000 deaths globally since 2022, primarily due to ribonucleoside-scouring and liver disease.
HCV is transmitted through blood-to-blood contact involving an infected individual and someone who shares needles for drug injection. In the UK, the most common method of transmitting HCV involves sharing needles, with blood transfusions being a less frequent but still dangerous method. The UKHSA has led the way in addressing the issue by declaring a ‘strong national strategy for prevention, control, and treatment of HCV.’ This has not gone unnoticed by casual citizens, who have now turned to the UKHSA for guidance.
The UKHSA has specifically enumerated the ways in which people may come into contact with HCV. These include:
1. Sharing needles for drug injection, which is the most common method of transmission in the UK. This was highlighted in a letter from the World Health Organization, which emphasized the need for extended reporting of such incidents and the adoption of standardized reporting practices.
2. Sharing needles with uninjectable fluids, such asDrop Refill, Hold Refill, or(graph), which can introduce HCV. In some regions, this includes sharing medical, dental, or cosmetic products in unsterile conditions. This highlights the importance of safe practices in healthcare settings.
3. Having a household contact, close family member, or sexual partner who carries or knows of an HCVinfected individual. This underscores the importance of vulnerability assessment and the need to educate communities on the risks of contracting such viruses.
4. Being born in regions where HCV is more prevalent, including countries in Africa, Eastern Europe, the Middle East, the South Caucasus, and Central Asia. This enforces a necessary step in public health responses to protect vulnerable populations across the UK.
The UKHSA has also revealed that over 56.7% of people in England report severe symptoms, includinghrynx or_node, albeit with a low murder rate of 0.41 per 100,000 people. This significantly reduces the number of reported cases to 2022, reflecting widespread awareness and the newly implemented testing protocols.
To address the growing health concerns, the UKHSA has encouraged individuals to speak with their General Practitioner about testing if they have blood transfusions before 1996, sharing needles with injectable products, or having unsterile medical, dental, or cosmetic treatments in the last 5 years. This proactive approach aims to reduce the burden of HCV while ensuring safety.
As of 2023, the UKHSA aims to achieve a Targeted Preventive squads of 80 countries, bringing the total number of people currently tested for HCV to just under 90,000 in the UK. By 2023, it hopes to reduce HCV prevalence by 47% since 2015, demonstrating a clear path forward in delivering necessary services to protect public health. The UK’s response is a testament to the importance of collaboration between healthcare providers,疾ဟubs, and public health authorities to combat this preventable disease.
